Letrozol Teva

Letrozole, the active ingredient in Letrozol Teva, is an aromatase inhibitor presented as a tablet for oral use. It treats hormone receptor‑positive breast cancer in postmenopausal women.

GNH USA supplies Letrozol Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Letrozole is used in the management of estrogen‑dependent breast cancer, targeting hormone‑receptor‑positive disease.

- Hormone receptor‑positive breast cancer in postmenopausal women: reduces estrogen production to inhibit tumor growth. - Advanced hormone receptor‑positive breast cancer: slows disease progression in metastatic settings. - Early‑stage hormone receptor‑positive breast cancer (adjuvant setting): lowers risk of recurrence after surgery.

Letrozole may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Hot flashes - Joint and muscle pain - Fatigue - Nausea or mild gastrointestinal upset

Serious or Rare Side Effects: - Severe liver injury - Osteoporotic fractures - Pulmonary embolism or deep‑vein thrombosis - Severe allergic reactions such as Stevens‑Johnson syndrome

When prescribing Letrozole, clinicians should consider several safety measures. - Monitor bone health: assess risk of osteoporosis and consider calcium/vitamin D supplementation. - Assess liver function: perform baseline and periodic liver enzyme tests. - Evaluate cardiovascular risk: monitor lipid profile and blood pressure. - Avoid use in premenopausal women: drug is indicated for postmenopausal patients only. - Store at room temperature: keep in original container, protect from moisture and light.

Letrozole interacts with several medicines that may alter its efficacy or safety.

Major Interactions (Avoid): - Concurrent estrogen‑containing hormone therapy: negates therapeutic effect. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): markedly reduce plasma levels. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase exposure and toxicity.

Moderate Interactions (Monitor Closely): - Warfarin: potential increase in anticoagulant effect; monitor INR. - Tamoxifen: possible antagonistic effect on estrogen modulation. - Selective serotonin reuptake inhibitors: may exacerbate hot flashes.